Indivior


Indivior develops, manufactures and sells buprenorphine-based prescription drugs for the treatment of opioid dependence worldwide. The Company’s product candidates focus on treating opioid use disorder, alcohol use disorder, overdose rescue and CNS disorders/schizophrenia. It markets and promotes Suboxone sublingual film, Suboxone sublingual tablet and Subutex sublingual tablet, as well as sells legacy analgesic products that include Temgesic, Burpex and Buprenex.

Company Growth (employees)
Type
Public
HQ
Slough, GB
Size (employees)
934 (est)+13%
Indivior is headquartered in Slough, GB

Indivior Office Locations

Indivior has offices in Slough, Richmond, Ottawa, Mannheim and in 11 other locations
Slough, GB (HQ)
105 Bath Rd
Beijing, CN
1 Dong San Huan Zhong Lu
Massy, FR
15 Rue Ampère
Milano, IT
7 Via Giovanni Spadolini
Mannheim, DE
3 Hermsheimer Str.
Ottawa, CA
2 Gurdwara Rd
Show all (15)

Indivior Financials and Metrics

Indivior Financials

Indivior's revenue was reported to be £819.4 m in FY, 2016 which is a 18% increase from the previous period.
GBP

Revenue (FY, 2016)

819.4 m

Revenue growth (FY, 2015 - FY, 2016), %

18%

Gross profit (FY, 2016)

736.5 m

Gross profit margin (FY, 2016), %

90%

Net income (FY, 2016)

27.1 m

Market capitalization (31-Oct-2017)

2.7 b

Closing share price (31-Oct-2017)

3.5

Cash (31-Dec-2016)

535.9 m
Indivior's current market capitalization is £2.7 b.
GBPFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

799.6 m762.9 m693.8 m819.4 m

Revenue growth, %

(5%)(9%)18%

Cost of goods sold

68.4 m65 m66.4 m82.9 m

Gross profit

731.2 m697.9 m627.4 m736.5 m
GBPFY, 2013FY, 2014FY, 2015FY, 2016

Cash

4.6 m226.5 m361.7 m535.9 m

Accounts Receivable

111.1 m110.8 m130.9 m158.8 m

Current Assets

149.9 m386.6 m558.4 m766.7 m

PP&E

121.7 m62.3 m119.3 m105.3 m
GBPFY, 2013FY, 2014FY, 2015FY, 2016

Cash From Operating Activities

520.2 m301 m247.8 m315.2 m

Cash From Financing Activities

(530 m)(61.6 m)(111.5 m)(113.8 m)

Income Taxes Paid

(135.5 m)(108.1 m)(44.1 m)(48.8 m)
Y, 2016

Financial Leverage

-4.1 x
Show all financial metrics

Indivior Operating Metrics

Indivior's Clinical Programs was reported to be 12 in FY, 2016
FY, 2016

Phase III Trials

4

Clinical Programs

12

Phase I Trials

4

Phase II Trials

1
Show all operating metrics

Indivior Market Value History

Indivior's Web-traffic and Trends

Indivior Company Life and Culture

You may also be interested in